SCHEMBL31509839

SCHEMBL31509839

CN(C(=O)Cl)c1ncccc1CN(CC(=O)OCc1ccccc1)C(=O)OCOP(=O)(OCc1ccccc1)OCc1ccccc1

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CASP3 P42574 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ SENP8 Q96LD8 1/20 0.34
▸ SENP7 Q9BQF6 1/20 0.34
▸ SENP6 Q9GZR1 1/20 0.34
▸ POLB P06746 1/20 0.33
▸ KMT2A Q03164 1/20 0.32
▸ EGFR P00533 2/20 0.32
▸ RAF1 P04049 2/20 0.32
▸ MAP2K1 Q02750 2/20 0.32
▸ GAA P10253 1/20 0.31
▸ ALDH1A1 P00352 4/20 0.31
▸ KCNA5 P22460 1/20 0.31
▸ MAPT P10636 2/20 0.30
▸ HPGD P15428 1/20 0.30
▸ KDM4E B2RXH2 1/20 0.30
▸ MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31555442 0.93 PPARA (0.33) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL31510023 0.83 L3MBTL1 (0.35) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL31509752 0.80 — —
SCHEMBL31480877 0.76 HDAC1 (0.37) L3MBTL1TSHRKMT2AALDH1A1MAPT
SCHEMBL23084799 0.76 POLB (0.38) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL29868237 0.76 POLB (0.38) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL21121829 0.75 TSHR (0.40) L3MBTL1TSHRCASP3RAB9ASENP8
SCHEMBL31509780 0.74 PTK2 (0.30) —
SCHEMBL31480801 0.74 ALDH1A1 (0.44) L3MBTL1TSHRKMT2AALDH1A1MAPT
SCHEMBL31480709 0.73 CCR6 (0.41) L3MBTL1TSHRKMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. 2025-04-24 — — US disclosed
WO-2025080850-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-04-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250127801-A1 BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF SDHA, SDHB, DPYD L3MBTL1 4059/4885TSHR 4706/4885CASP3 348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback